title: Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
abstract: Forest Laboratories (following its acquisition of Cerexa Inc, a spin-out from Peninsula Pharmaceuticals Inc), under license from Takeda, is developing ceftaroline fosamil, an N-phosphono prodrug of ceftaroline, a derivative of a fourth-generation cephalosporin, for the potential treatment of methicillin-resistant Staphylococcus aureus infection. Phase III clinical trials evaluating ceftaroline fosamil for community acquired pneumonia and complicated skin and skin structure infections are underway.
authors.affiliation: Columbia University School of Medicine, 1090 Amsterdam Avenue, St Lukes Roosevelt Hospital Center, New York, NY 10025, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Parish
authors.forename: Noah
authors.initials: N
authors.lastname: Scheinfeld
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002511:Cephalosporins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016106:Methicillin Resistance; D015394:Molecular Structure; D010330:Patents as Topic; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013329:Structure-Activity Relationship; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline